netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

 Details...
08.01.03  Expand sub section  Antimetabolites
Cytotoxic Drug Azacitidine (Vidaza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes,chronic myelomonocytic leukaemia and acute myeloid leukaemia
Link  NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
   
Cytotoxic Drug Capecitabine (Xeloda®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Restriction: In line with NICE Guidance only

 
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Link  NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Link  NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
   
Cytotoxic Drug Cladribine (Mavenclad ®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

 

 
Link  NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Link  MHRA drug safety update: Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected
   
Cytarabine–daunorubicin liposomal
(Vyxeos®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Fludarabine phosphate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 
Link  NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Link  NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
   
Cytotoxic Drug Gemcitabine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 

 
Link  NICE NG85: Pancreatic cancer in adults: diagnosis and management
Link  NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Pemetrexed disodium
(Alimta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Link  NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Link  NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Link  NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
   
Cytotoxic Drug Tegafur with Uracil
(Uftoral®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red

Restriction: In line with NICE Guidance only

 

Uftoral was discontinued by manufacturer (March 2013)

 
Link  NICE TA61: Capcitabine and tegafur - Colorectal cancer
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary